Literature DB >> 8968017

Occult prostate cancer in men with low serum testosterone levels.

A Morgentaler1, C O Bruning, W C DeWolf.   

Abstract

OBJECTIVE: To determine the prevalence of occult prostate cancer in men with low serum total testosterone or free testosterone levels.
DESIGN: Retrospective analysis of a consecutive series of men.
SETTING: Academic teaching hospital. PATIENTS: Seventy-seven men with low total testosterone or free testosterone levels, with normal results of digital rectal examination and prostate-specific antigen (PSA) levels of 4.0 ng/mL or less. The mean age was 58 years.
INTERVENTIONS: Sextant prostate needle biopsies with ultrasound guidance. MAIN OUTCOME MEASURES: Results of prostate needle biopsies, transrectal ultrasound, prostate volume, PSA level, PSA density, total and free testosterone levels.
RESULTS: Prostate cancer was identified in 14% (11/77) of the entire group and in 10 men (29%) aged 60 years or older. The median age for men with cancer was 64 years. Histologic examination showed Gleason scores of 6 or 7 for all cancers. No significant differences were noted between the cancer and benign groups with regard to PSA level, PSA density, prostate volume, total testosterone level, or free testosterone level.
CONCLUSIONS: A high prevalence of biopsy-detectable prostate cancer was identified in men with low total or free testosterone levels despite normal PSA levels and results of digital rectal examination. These data suggest that (1) digital rectal examination and PSA levels are insensitive indicators of prostate cancer in men with low total or free testosterone levels, and (2) PSA levels may be altered by naturally occurring reductions in serum androgen levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968017

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  45 in total

1.  Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

Authors:  Eduard García-Cruz; Jorge Huguet; Marta Piqueras; Meritxell Pérez Márquez; Lluís Peri; Laura Izquierdo; Agustín Franco; Ricardo Alvarez-Vijande; María José Ribal; Antonio Alcaraz
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

2.  Androgen replacement therapy: treatment advances and clinical implications.

Authors:  Randall B Meacham
Journal:  Rev Urol       Date:  2003

Review 3.  The safety of testosterone supplementation therapy in prostate cancer.

Authors:  James M Dupree; Gavin M Langille; Mohit Khera; Larry I Lipshultz
Journal:  Nat Rev Urol       Date:  2014-07-29       Impact factor: 14.432

Review 4.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

5.  Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25-84 Years from the Busselton Health Study.

Authors:  Yi X Chan; Matthew W Knuiman; Mark L Divitini; David J Handelsman; John P Beilby; Bu B Yeap
Journal:  Horm Cancer       Date:  2018-08-10       Impact factor: 3.869

6.  Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.

Authors:  Göksel Bayar; Hakan Şirin; Mustafa Aydın; Ayşim Özağarı; Orhan Tanrıverdi; Mustafa Kadıhasanoğlu; Muammer Kendirci
Journal:  Turk J Urol       Date:  2017-08-01

Review 7.  Depression in aging men: the role of testosterone.

Authors:  Ryan M Carnahan; Paul J Perry
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Authors:  L Rinnab; K Gust; R E Hautmann; R Küfer
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

9.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

Review 10.  Testosterone replacement therapy and prostate cancer: a word of caution.

Authors:  Timothy C Brand; Edith Canby-Hagino; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.